Testing a new cancer drug plus capecitabine for metastatic colon cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies whether BEY1107, a new treatment, is safe and works better when combined with capecitabine in people with metastatic colorectal (colon/rectum) cancer. It is aimed at cancers that have already progressed after standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 19 or older and can give written informed consent
- You have confirmed colorectal cancer that has spread to sites that cannot be removed by surgery
- Your cancer has not responded to at least two rounds of standard chemotherapy (including fluorouracil-type drugs, oxaliplatin, and irinotecan)
- You can have imaging tests showing at least one measurable or trackable spot of cancer
- Your overall health is good enough for study treatment (ECOG 0–1)
- You can safely use birth control during the study and for a set time after the last dose (if you could become pregnant or have a partner who could)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a new immunotherapy drug (QL1706) to standard chemotherapy plus bevacizumab for people with colorectal cancer that has spread and hasn't been treated yet. It aims to see if the combination works better than standard treatment alone.
This trial tests a combination of two oral drugs, capecitabine and lenvatinib, in people with advanced colorectal cancer that has stopped responding to three common chemotherapy drugs. It aims to see if this new combination can help shrink tumors or slow cancer growth.
This trial tests a new drug (RC148) combined with standard chemotherapy as a first treatment for colorectal cancer that has spread or cannot be removed. The goal is to see if this combination works better than chemotherapy alone.
This study tests a combination of several cancer drugs (irinotecan, capecitabine, bevacizumab, and camrelizumab) in people with metastatic colorectal cancer who have already tried at least one prior treatment. The goal is to see if these drugs work better together for patients who don't have certain genetic features.
This trial tests a new drug, TQB2930, combined with chemotherapy (with or without bevacizumab) for advanced colorectal cancer that cannot be removed by surgery. It's designed for people whose tumors are HER2-positive and have not responded to standard treatments.
This trial is testing a new combination of drugs (envafolimab, cetuxima-β, and chemotherapy) for people with a specific type of advanced colorectal cancer that has not been treated yet. The goal is to see if it is safe and works well.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.